Provided by Tiger Fintech (Singapore) Pte. Ltd.

Syros Pharmaceuticals

0.0924
+0.015920.78%
Post-market: 0.0820-0.0104-11.26%19:59 EDT
Volume:81.32M
Turnover:8.90M
Market Cap:2.48M
PE:-0.03
High:0.1275
Open:0.0800
Low:0.0765
Close:0.0765
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney

Reuters
·
12 Mar

Stocks to Watch: Toro, Syros Pharmaceuticals

Dow Jones
·
01 Mar

Syros Pharmaceuticals Delists from Nasdaq Amid Restructuring

TIPRANKS
·
01 Mar

Syros Pharmaceuticals Plans to Wind Down Operations

Dow Jones
·
01 Mar

Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares

MT Newswires Live
·
01 Mar

Syros Pharmaceuticals trading resumes

TIPRANKS
·
01 Mar

Syros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stock

TIPRANKS
·
01 Mar

Syros Pharmaceuticals trading halted, news pending

TIPRANKS
·
01 Mar

Syros Pharmaceuticals Inc - to File Form 25 With Securities and Exchange Commission for Delisting on March 10, 2025

THOMSON REUTERS
·
01 Mar

Syros Announces Voluntary Delisting From Nasdaq and SEC Deregistration

THOMSON REUTERS
·
01 Mar

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

Business Wire
·
01 Mar

BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes

Reuters
·
19 Nov 2024

Syros Pharmaceuticals Inc - Termination Will Be Effective 90 Days Following Such Notice

THOMSON REUTERS
·
18 Nov 2024

Syros Pharmaceuticals Inc - Appointment of Gerald Quirk, Esq., as President & CEO

THOMSON REUTERS
·
18 Nov 2024

Syros - Notified Conley Chee,CEO ,Jason Haas,CFO, David Roth, Chief Medical Officer That Employment of Such Officers Will Terminate Without Cause

THOMSON REUTERS
·
18 Nov 2024

Syros Pharmaceuticals Inc - on Nov 15, Paid $33.5 Mln to Oxford in Partial Satisfaction of Its Obligations Under Loan Agreement

THOMSON REUTERS
·
18 Nov 2024